Topics on the BUS-13:
- Advancement on Difficult Airway Management
Dr. Huafeng Wei, MD, PhD, Associate Professor of Anesthesiology and Critical Care, Hospital of the University of Pennsylvania, USA. President of the International Airway Management Society (IAMS).
His lab has focused on studying the role of calcium dysregulation in neurodegeneration and cognitive dysfunction in various neurodegenerative diseases, especially in Alzheimer’s disease and after various general anesthetics treatments. His lab is the first to demonstrate that dantrolene, a drug for treatment of malignant hyperthermia, can abolish the memory and learning impairment in an animal model of Alzheimer’s disease, even as a disease-modifying drug. Dr. Wei’s Lab also illustrated the mechanism of general anesthetics’ dual effects on both neuroprotection and neurotoxicity via differential regulation on intracellular calcium homeostasis and provide guidance for clinical practice.
Dr. Wei has been an invited speaker for Harvard, Johns Hopkins, UCSF, Duke, UVA, Imperial College of England, University of Heidelberg in Germany, University of Padova in Italy, as well as speakers for international conferences in more than 10 countries and regions.
Dr. Wei is the inventor of the WEI Nasal Jet Tube (WEI NASAL JET, WNJ) and “WEI jet endotracheal tube (WEI JET)”, two novel airway devices providing supraglottic jet oxygenation and ventilation (SJOV), a new concept and noninvasive technique to augment the oxygenation and ventilation. SJOV via WNJ and/or WEI JET is expected to reduce hypoxia/hypercapnia associated morbidity and mortality in patient with significant respiratory depression or apnea or during elective or difficult airway management.